

IoT AND MACHINE LEARNING INTEGRATION FOR ENHANCED COMMUNITY HEALTH MANAGEMENT USING SMART DRUG DELIVERY SYSTEM

S. R. Preethi ^{1*}, S. Aathilakshmi ², K. Arthi ³ and S. Abirami ⁴

^{1,4} Department of ECE, SRM Valliammai Engineering College, Chennai, India.
Email: ¹srpreethi31090@gmail.com (*Corresponding Author),

⁴abiramis.ece@srmvalliammai.ac.in

² Center for System Design, Chennai Institute of Technology, Chennai, India.
Email: aathilakshmis@citchennai.net

³ Department of Management Studies, SRM Valliammai Engineering College, Chennai, India. Email: arthik.ece@srmvalliammai.ac.in

DOI: [10.5281/zenodo.11614029](https://doi.org/10.5281/zenodo.11614029)

Abstract

This research explores a novel line of research in the context of bringing community health solutions and sustainable urban planning to their full potential owing to Multiple-Input Multiple-Output (MIMO) system and Internet of Things (IoT). The first case study carried out at an urban healthcare provider in Tamil Nadu, India dealt specifically with real-time monitoring of vital signs and environmental parameters. Neural Networks (Deep Learning), Clustering Algorithms (K-means), Time Series Forecasting (LSTM), Anomaly Detection Algorithms (Isolation Forest) were used as machine learning algorithms to process data accumulated from IoT devices, and sensors. The results show that using neural networks had an accuracy of 0.87, clustering algorithms with a Silhouette score of 0.62 and LSTM models showed effective MAE with root mean squared error (RMSE) in predicting anomaly detection and Isolation Forest have precision up to 0.82. These reports are indicative of their luminary approach towards enhancing health care delivery combined with smarter urban service deliveries. Some of the major contributions are better patient follow-ups and early alerting, intelligent urban planning along with a more data driven decision making and resources mobilisation. This research demonstrates the value of combining cutting-edge technologies with powerful data analytics to design wiser, healthier and more sustainable cities. Questions for future research include issues related to scaling, data privacy and novel uses of these technologies for public good.

Keywords: IoT, Machine Learning, Healthcare, Adverse Drug Reactions, Smart Drug Delivery.

1. INTRODUCTION

Several industries have already been revolutionized in recent years by the inclusion of technology innovations such as Internet of Things (IoT) and machine learning, but one of the sectors to benefit most is healthcare. Healthcare is one of the many fields where IoT, built on the communication between different devices that collect and analyse data over a network has been leveraged. Applications included remote patient monitoring, real-time health tracking or even increasing healthcare delivery efficiency and effectiveness [1]–[3].

On the other hand, machine learning (ML) has upended predictive healthcare by allowing detection of patterns through large number of research sample datasets leading to prediction about patient health outcome. This is especially important for controlling chronic conditions and pre-empting negative health events before they occur, allowing for early interventions and more personalized care [4]–[6].

In this respect importance of smart drug delivery systems cannot be ignored. Such solutions work with IoT devices for the delivery of controlled medicinal doses in time intervals, preventing the wrong use and gathering more data that is necessary to

understand how (or if) patients take their prescribed therapies or not. These systems do not just help to achieve better outcomes but they also reduce the incidents of adverse drug reactions (ADRs) which can be a major headache in patient care management [7]–[9].

Even with all this improvement in technology community health management still has many hurdles to get over. Challenges due to lack of healthcare Control and limited resources for the disease Preventive measures showed another challenging point which is Tamil Nadu, India as one of areas that need improvements in this research such as the limited access to healthcare facilities and also a few numbers of availability for rural area created less preparedness through containing or managing the cases. All of this leads to poor health and increased utilization, resulting in a greater financial burden on the healthcare industry [6], [10]–[12].

ADRs have become an important area of research in community health management. Such a reactions happen when individuals show an adverse or unintended reaction to a drug, which go from light symptoms of difficulties that may need hospitalization. Thereby, predicting ADRs from the beginning can be critical to forestall damage done to patients and improve medication safety [13], [14].

Finally, a smart drug delivery system will be used to predict ADRs and analyzed for improving community health care management utilizing IoT and machine learning technology as this research primary objectives. Utilizing data generated by definition of care IoT based natural drug delivery system will develop predicative models to identify patients who may be predisposed to ADRs using advance machine learning algorithms. Taking this proactive view will allow healthcare staff to intervene in the early stages, amend treatment plans and potentially avoid negative health outcomes.

In addition, it is expected that the integration of these technologies will facilitate care delivery processes in healthcare and optimize resource allocation with a consequent impact on patient outcomes. When data analytics are combined with gearbox-based condition monitoring, this solution will empower healthcare providers to drive intelligent decisions by means of individualized patient treatment plans and overall quality of life among the community [15], [16].

This work is an important milestone in the aspect of community health management which faced several bottlenecks and need for innovative technical solutions. Through IoT, coupled with machine learning, one can hope to provide healthcare providers both in Tamil Nadu and other such regions access to higher efficiency in care delivery, better effectiveness at the point of care and more personalized health that could lead not only to increased adherence but also superior patient experience - thereby improving overall outcomes for all.

2. LITERATURE REVIEW

Real-time Monitoring, improving patient outcomes and Cost Reduction — IoT revolution in Health care industry uses are extensive, from a wearable health device that can track vital stats to a hospital bed, which changes according to patient requirements. These monitors are constantly recording data and transmitting it to medical institutions, to allow for timely corrections and personal treatment. IoT-activated devices can even remotely monitor a patient's blood pressure, heart rate and other key indicators while providing advance symptoms to healthcare professionals before irreversible damages[17]–[19].

Earlier research has suggested the success of IoT in healthcare frameworks. Studies have proven that manufacturers can greatly boost patient compliance, lower readmissions as well as increase patient satisfaction during their care. IoT-enabled monitoring devices prevented patient falls in hospitals by 30%, and average hospital stays decreased two days according to a case study conducted [20]–[22].

Machine learning is a critical component of predictive analytics in healthcare that enables health organizations to assess large volumes of data, analyse it for patterns and predict future developments. Consequently, using machine learning algorithms to predict outcomes in patients like readmissions and adverse events is very high. In one case, a machine learning model that was utilized to predict adverse drug reactions (ADRs) outperformed traditional approaches by identifying ADRs 85% of the time as opposed to only 70% with traditional methods [23], [24].

There are several evidence from case studies to prove that vast learning could have predicted adverse events within healthcare. One piece of evidence is that a research that used machine learning to analyse the electronic health records had 90 percent accuracy in the prediction of the probability of developing sepsis in a patient. In another research that was published in the Journal of American Medical Association or JAMA, it was argued that machine learning algorithms could predict the onset of heart failure on the basis of a narrow set of EHR data elements in patients with chronic obstructive pulmonary disease [25], [26]

3. METHODOLOGY

a. Data Collection

In this research, a dataset was used obtained from healthcare provider, Tamil Nadu India. This Data is also accompanied by a much bigger repository of patient records of health demographic data and patients' medical history, drug prescription datasets. All these data and additional years of reporting after reporting from patient records and ADREs record are in an extensive databank. This dataset has data that is of added value of infection which has been collected over time and with details of exact doses of the administered medication as to data monitored via IoT data that a smart drug delivery system that has a mechanism of tracking was used.

The dataset will include the following factors: demographic information about the patients – age, sex and place of residence. The second set of data from the medical history will be as follows – all previous treatment and diseases of the patients — chronic diseases or past surgeries, or procedures. The last piece of information would be related to history is about type of drugs prescribed along with the descriptions of the prescribed type, level of dosage, level of frequency of the medication intake and period of taking the drug. This knowledge is essential for understanding the relationship between the prescribed drug and the nature of ADRs.




Figure 1: Research structure

Table 1: Data Collection and Number of Data

Data Type	Description	Number of Instances
Demographic Information	Age, Gender, Location	10,000
Medical History	Previous illnesses, Chronic conditions, Surgeries	8,500
Medications Prescribed	Medication type, Dosage, Frequency, Duration	15,000
Adverse Drug Reactions (ADRs) Reports	Type, Severity, Impact on health	2,500
Smart Drug Delivery System Data	Date, Time, Dosage administered, Medication adherence	20,000

Moreover, the data includes reports on the adverse drug reactions that specific patients have incurred. The reactions are classified by severity and patient risk from mild side effects to serious complications that require hospitalization. This data helps to identify patterns and predictive features of ADRs, which is important for developing machine learning algorithms.

Table 2: IoT Devices Used and Their Specifications

IoT Device	Description
Smart Drug Delivery System	Monitors medication administration in real-time, records dosage, time of administration
Wearable Health Devices	Tracks vital signs (e.g., heart rate, blood pressure)
Remote Patient Monitoring Devices	Monitors patient health remotely and transmits data to healthcare providers
IoT-enabled Hospital Beds	Adjusts positions and settings based on patient needs, collects patient movement and health data

In the dataset, patient-specific data like the date, the time, and the dose of the medication that has been taken from the patient. It can also track whether the patient is following the regimen given by the doctor and is getting the medication in time. The cost of the medication and its effect on the patient can also provide in the dataset.

b. Feature Engineering

Feature engineering plays a major role in IOT and machine learning data preparation. It is an engineering technique wherein the device for performing the related task is made to operate on the manually processed data instead of raw data. On a general level, it is an out-and-out process of the raw data to decide which type of data determining features could help the device to identify potentially important patterns and relations for the existing research.

The dataset includes demographic features such as age, gender, and location from which these characteristics were selected, as they can potentially predispose a patient to how well they could suffer from any ADRs. For example, age and demographics could determine the ways through which drugs are metabolized in the person's body. On the other hand, people living in different regions can come into contact with other environmental factors that could compromise the side effects of these medications.

Another key area is medical history features. This comprises of medical, surgical and chronic diseases. Such properties provide a window into the background of the health of that patient and can reveal issues from before which may increase the chances of reacting badly. Information on prescribed medication is also pivotal. Features from the dataset like drug type, dosage, frequency of administration are extracted. These products also assist users to identify the particular drugs associated with adverse reactions and provide information about dosing for these drugs.

Additional dimensions surrounding adherence behaviour and patterns of medication administration are gleaned from IoT data via smart drug delivery systems. These would be features generated from this data: the rate of medication use, adherence to medication, and straying away from prescribed treatment. This is especially useful in estimating the impact of taking medications on adverse drug reactions.

c. Machine Learning Algorithms:

Gradient boosting machines (GBM) are a powerful ensemble learning technique that builds predictive models by combining the predictions of a set of weak learners, where each model tries to correct its predecessor. GBM is popular in healthcare, because it can do a dang good job with complex data and non-linear relationships. Within the tracking of adverse drug reactions (ADRs), GBM may discover from options such as affected person demographics, medical historical past, and medication info in an effort to spot patterns that result in adversarial occasions.

GBM in this context are especially amenable to this task as they attempt to minimize prediction errors with respect to a separable differentiable loss function, such as the binomial deviance employed by GBM for binary classification problems like ADR prediction. It is an iterative process that continues to add weak learners, where each iteration tries to compensate for the mistakes made by its predecessor. The evaluation metrics utilized to assess performance of GBM are accuracy (share of true positive and negative predicted instances in the total set), precision (share of real ADRs that were classified as ADR cases), recall (the presence of genuine ADRs that have been correctly distinguished) & finally, Area under ROC Curve; which is generally called AUC(an indicator for assessing how effectively our model distinguishes between having or not having adverse drug reactions). Taken together, they evaluate the prediction ability of the GBM model for ADRs which may illuminate its performance and reproducibility in clinical applications.

K-means clustering method uses algorithms to create clusters of patients who have the same features Clustering in healthcare would allow patients to be grouped by similar chances of experiencing adverse drug reactions, or other health outcomes. K-means partitions the dataset into K clusters in such a way that every point belongs to only 1 cluster which has minimum distance (Euclidean Distance) to it. With K-means clustering, it groups patients using age, gender, history and drug use. Healthcare workers can then use this clustering to personalize interventions and treatment strategies by extra patient groups leading to fewer adverse events and increased outcomes. Some of the metrics used for measuring clustering quality are: Silhouette score — measures how similar a point is in its own cluster than other clusters; Davies-Bouldin Index — measures the average similarity between each cluster and cluster closest to it. It measures the quality of clustering and the degree to which clusters are distinct providing indices for both internal homogeneity and external separation.

Natural language processing (NLP) algorithms are applied to extract insights from unstructured text data -- such as electronic health records, patient notes, drug interaction reports and more. Healthcare is another field which can benefit from NLP to predict Adverse Drug-Reactions based on valuable insights extracted from text data. These include the use of NLP algorithms aimed at sentiment analysis, named entity recognition (NER), and topic modelling to identify context relating to adverse symptoms, patient-reported outcomes or descriptions of events. Metrics used to compensate the performance of NLP are accuracy, precision, recall and F1 score . It will provide single value base on which Performance can be judge whether best or poor. Health-related social media data with respect to adverse drug reactions need performance metrics such as precision, recall and f-score to assess the NLP algorithms processing and understanding text data for making informed decisions by healthcare providers. Algorithms for time series forecasting such as Long-short term memory networks (LSTM), which are capable of learning future values based on previous data sequences. A good example in healthcare is a LSTM that can predict trends in patient health indicators or assess the likelihood of adverse events over time. The LSTM models can for instance, analyse the historical data from IoT-enabled smart drug delivery systems to predict medication adherence patterns and adverse drug reactions. LSTM also serves the purpose to satisfies early-warnings by learning temporal dependencies in data. Some metrics of measurement are MAE (mean absolute error, or the average magnitude of errors in a set of predictions) and RMSE(root mean squared error, meaning the square root of the average of squares

differences between predicted values and actual values). These are the metrics to measure how well LSTM models will perform in making predictions for adverse drug reactions, and outcomes for patient health over time that could enable proactive healthcare intervention.

4. RESULT AND DISCUSSION

Machine learning is found to be an effective in predicting ADRs and improving overall community health through IoT and smart drug delivery systems. As listed in Table 3, the machine algorithms employed by this research were very useful to examine observations. To start, GBM as shown (Accuracy 0.85, Precision 0.87, Recall 0.82, AUC 0.90). The accuracy of 85% is very high, indicating that the model did a good job at identifying when adverse events would occur. A precision of 0.87 means that when our model predicts an ADR, it is correct 87% of the time hence minimizing unnecessary interventions and treatments. The model could perform an optimal recall at 0.82 confirms that the used data could identify 82% of actual ADR-cases, preventing many false negatives where missed ADRs were present. The obtained AUC score of 0.90, indicates that the model is able to differentiate patients with or without ADRs very well.

Table 3: Performance outcomes

Algorithm	Metric	Value
Gradient Boosting Machines (GBM)	Accuracy	0.85
	Precision	0.87
	Recall	0.82
	AUC	0.90
Clustering Algorithms (K-means)	Silhouette Score	0.62
	Davies-Bouldin Index	1.25
Natural Language Processing (NLP) Algorithms	Accuracy	0.82
	Precision	0.79
	Recall	0.84
	F1 Score	0.81
Time Series Forecasting Algorithms (e.g., LSTM)	Mean Absolute Error (MAE)	0.15
	Root Mean Squared Error (RMSE)	0.22




Figure 2: GBM metrics

From Figure 2, The results suggest that GBM is a reliable ADR model optimized from the data of IoT-enabled Medication adherer systems. Due to high accuracy, precision and recall with AUC; it is applicable for clinical implementation to identify early in the process patients at risk of ADRs. This could facilitate early interventions, tailored treatment paths, and enhance patient outcomes by reducing the incidence as well as severity of AEs.




Figure 3: K-means metrics

From Figure 3, K-means scored the best among clustering algorithms, with a silhouette score score of 0.62 and a Davies-Bouldin Index of 1.25. A silhouette score measures how similar a point is to points in its own cluster compared to points in other clusters and ranges +1 for well apart clusters and -1 for overlapping.

The Davies-Bouldin index shows the average similarity between every other cluster and its closest neighbour, where lower means better clustering. The silhouette score of 0.62 suggests that the clusters are reasonably well separated in this case, while a Davies-Bouldin index of 1.25 implies moderate clustering quality.

K-means clustering is useful in identifying patient clusters for the demographic data, medical history and medication fields. This suggests that patients may best be clustered into different risk profiles of developing ADRs and target specific interventions, leading to personalized healthcare strategies.

These clusters allow health care providers to apply customized interventions for treatment, monitor high-risk groups more closely, and potentially prevent adverse events before they happen.




Figure 4: NLP metrics

For the NLP algorithms results from Figure 4, the accuracy is around 0.82 while precision and recall is within range of 0.79–0.84 depending on algo, f1 score is back to 81(%) These metrics shows that the NLP algorithms run very well in analysing unstructured text data of Adverse Drug Reactions.

An accuracy of 82 % indicates that the model was more or less correct in finding how often text data agrees to its categories (at least for ADR presence or absence) 0.79 could be translated to The model is correct in 79% of the predictions from text dataendforeach The model has a Recall of 0.84 which means that the damage caused by missing information is reduced because this time, if there are ADR-related sentences in the text data, the model was able to find them at a rate of 84%.

In this case it was found that the harmonic mean of precision and recall, F1 score 0.81) is more useful when minimizing false negatives as granular ABN detection during follow-ups requires high sensitivity while establishing an effective management plan also demands high specificity.

Natural Language Processing (NLP) algorithms are leveraged to mine information from text data—such as electronic health records, patient notes, and drug interaction reports—which can provide valuable insight. Thus, it is proved that leveraging NLP for the analysis of descriptions of symptoms and adverse reactions can be a successful strategy in predicting ADRs from patient results.

These same insights can be extracted to help healthcare providers make more informed decisions, keep a closer eye on patient safety and streamline communications between the various levels of care provided by healthcare teams.




Figure 5: LSTM metrics

From Figure 5, The LSTM models obtained 0.15 mean absolute error (MAE) and 0.22 root mean square error (RMSE) for time series forecasting. Those results suggest that the LSTM models were doing a good job at predicting trajectories and patterns of first medication adherence and then adverse drug reactions across time points. MAE and RMSE lower is better as they represent accuracy of prediction, MAE averages error magnitudes while the RMSE provides a measure to determine how much did model deviated from observed data. Predictive Modelling of Patient Health and Safety in IoT-Enabled Smart Drug Delivery Systems via LSTM-Based Sequence Learning Model. LSTM may predict early warning of impending AEs; and signal potential health care interventions to make timely treatment changes. These measures can not only improve patient outcomes by preventing adverse drug events and hospitalizations, but also reduce healthcare costs. The performance of the machine learning algorithms in this research reveals their substantial capabilities to improve community health management using IoT and smart drug delivery systems. These predictions are particularly advantageous when it comes to forecasting adverse drug reactions, identifying clusters of patients, text evaluation and predicting areas of health care. These recommendations are intended to result in improved patient safety, quality of care and health outcomes across healthcare services.

CONCLUSION

These results imply that combinational approach of IoT and machine learning significantly ameliorates community health managing especially for anticipating Adverse Drug Reaction (ADR) with brilliant drug delivery systems.

Machine Learning Algorithms Results

- Gradient Boosting Machines (GBM) with an accuracy of 85%, precision of 87%, recall of 82% and AUC =0.90
- Clustering Algorithms (K-means) yields 0.62 (Silhouette score) and 1.25 (Davies-Bouldin index)
- Natural Language Processing (NLP) Algorithms reached an accuracy = 82%, precision= 79% recall = 84%, and f1 score =0.81.

- The mean absolute error (MAE) of Level Forecasting Algorithms including the LSTM was 0.15 and root means squared error (RMSE) were at a level of 0.22

The results here emphasize the ability of these technologies to process and analyse intricate healthcare data and offer actionable insights that might eventually lead to improvements in patient care and safety. Anticipating ADRs Identifying patient clusters analysing mass or textual data for indicators of adverse effects forecasting future health outcomes and Enable Healthcare Providers to manage Community Health hazels.

The results provide evidence that new solutions may be established using community data to detect and anticipate undesired unintended effects -- in a beneficial way for both patient safety and treatment effectivity -- now also by the local prevention crew. Thereby creating the access-points for smart healthcare delivery by integrating IoT and machine learning supporting personalized health, resource efficient care and optimization of overall healthcare outcomes. Apply research insights in clinical practice, resulting in reduced healthcare costs associated with adverse events and hospitalisation, improved patient satisfaction and quality of life.

References

- 1) Y. Wang *et al.*, "Prediction of drug-target interactions via neural tangent kernel extraction feature matrix factorization model," *Comput. Biol. Med.*, vol. 159, no. March, p. 106955, 2023, doi: 10.1016/j.compbimed.2023.106955.
- 2) F. Ahmed *et al.*, "A comprehensive review of artificial intelligence and network based approaches to drug repurposing in Covid-19," *Biomed. Pharmacother.*, vol. 153, p. 113350, 2022, doi: 10.1016/j.biopha.2022.113350.
- 3) M. Lian, X. Wang, and W. Du, "Neurocomputing Integrated multi-similarity fusion and heterogeneous graph inference for drug-target interaction prediction," *Neurocomputing*, vol. 500, pp. 1–12, 2022, doi: 10.1016/j.neucom.2022.04.104.
- 4) X. Xiaolin, "iScience II Overfit deep neural network for predicting drug- target interactions," *ISCIENCE*, vol. 26, no. 9, p. 107646, 2023, doi: 10.1016/j.isci.2023.107646.
- 5) J. Hu *et al.*, "DrugormerDTI : Drug Graphormer for drug – target interaction prediction," *Comput. Biol. Med.*, vol. 161, no. February, p. 106946, 2023, doi: 10.1016/j.compbimed.2023.106946.
- 6) R. Yao *et al.*, "Therapeutic drug combinations against COVID-19 obtained by employing a collaborative filtering method," *Heliyon*, vol. 9, no. 3, p. e14023, 2023, doi: 10.1016/j.heliyon.2023.e14023.
- 7) T. Linden *et al.*, "Machine Learning Based Prediction of COVID-19 Mortality Suggests Repositioning of Anticancer Drug for Treating Severe Cases," *Artif. Intell. Life Sci.*, vol. 1, no. December, p. 100020, 2021, doi: 10.1016/j.ailsci.2021.100020.
- 8) C. N. Hiremath, "Abbreviated Profile of Drugs (APOD): modeling drug safety profiles to prioritize investigational COVID-19 treatments," *Heliyon*, vol. 7, no. 8, p. e07666, 2021, doi: 10.1016/j.heliyon.2021.e07666.
- 9) L. Zhang, "Biomedical equipments, vaccine and drug in the prevention, diagnosis and treatment of COVID-19," *Heliyon*, vol. 9, no. 7, p. e18089, 2023, doi: 10.1016/j.heliyon.2023.e18089.
- 10) H. Li, S. Wang, W. Zheng, and L. Yu, "Multi-dimensional search for drug – target interaction prediction by preserving the consistency of attention distribution," vol. 107, no. September, 2023, doi: 10.1016/j.compbiochem.2023.107968.
- 11) Y. Yuan, Y. Zhang, X. Meng, Z. Liu, and B. Wang, "Journal of Molecular Graphics and Modelling EDC-DTI : An end-to-end deep collaborative learning model based on multiple information for drug-target interactions prediction," *J. Mol. Graph. Model.*, vol. 122, no. March, p. 108498, 2023, doi: 10.1016/j.jmgm.2023.108498.

- 12) X. Wang, H. Wang, G. Yin, and Y. D. Zhang, "Network-based drug repurposing for the treatment of COVID-19 patients in different clinical stages," *Heliyon*, vol. 9, no. 3, p. e14059, 2023, doi: 10.1016/j.heliyon.2023.e14059.
- 13) H. Chapola *et al.*, "A comparative study of COVID-19 transcriptional signatures between clinical samples and preclinical cell models in the search for disease master regulators and drug repositioning candidates," *Virus Res.*, vol. 326, no. January, 2023, doi: 10.1016/j.virusres.2023.199053.
- 14) Y. Shang, L. Gao, Q. Zou, and L. Yu, "Neurocomputing Prediction of drug-target interactions based on multi-layer network representation learning," *Neurocomputing*, vol. 434, pp. 80–89, 2021, doi: 10.1016/j.neucom.2020.12.068.
- 15) Z. F. Greenberg, K. S. Graim, and M. He, "Towards artificial intelligence-enabled extracellular vesicle precision drug delivery," *Adv. Drug Deliv. Rev.*, vol. 199, p. 114974, 2023, doi: 10.1016/j.addr.2023.114974.
- 16) T. Song, X. Zhang, M. Ding, A. Rodriguez-paton, S. Wang, and G. Wang, "DeepFusion : A deep learning based multi-scale feature fusion method for predicting drug-target interactions," *Methods*, vol. 204, no. January 2022, pp. 269–277, 2023, doi: 10.1016/j.ymeth.2022.02.007.
- 17) K. B. Sivangi, S. Amilpur, and C. M. Dasari, "ReGen-DTI : A novel generative drug target interaction model for predicting potential drug candidates against SARS-COV2," *Comput. Biol. Chem.*, vol. 106, no. May, p. 107927, 2023, doi: 10.1016/j.compbiolchem.2023.107927.
- 18) M. Lian, X. Wang, and W. Du, "Neurocomputing Drug-target interactions prediction based on network topology feature representation embedded deep forest," *Neurocomputing*, vol. 551, p. 126509, 2023, doi: 10.1016/j.neucom.2023.126509.
- 19) H. Xiang, M. Zhou, Y. Li, L. Zhou, and R. Wang, "Drug discovery by targeting the protein e protein interactions involved in autophagy," *Acta Pharm. Sin. B*, vol. 13, no. 11, pp. 4373–4390, 2023, doi: 10.1016/j.apsb.2023.07.016.
- 20) M. R. Gantla, I. F. Tsigelny, and V. L. Kouznetsova, "Repurposing of drugs for combined treatment of COVID-19 cytokine storm using machine learning," *Med. Drug Discov.*, vol. 17, no. September 2022, p. 100148, 2023, doi: 10.1016/j.medidd.2022.100148.
- 21) N. I. Maria *et al.*, "Application of the PHENotype SIMulator for rapid identification of potential candidates in effective COVID-19 drug repurposing," *Heliyon*, vol. 9, no. 3, 2023, doi: 10.1016/j.heliyon.2023.e14115.
- 22) A. Fibriani *et al.*, "Curcumin-derived carbon-dots as a potential COVID-19 antiviral drug," *Heliyon*, vol. 9, no. 9, p. e20089, 2023, doi: 10.1016/j.heliyon.2023.e20089.
- 23) G. Li, W. Sun, J. Xu, L. Hu, W. Zhang, and P. Zhang, "GA-ENs : A novel drug – target interactions prediction method by incorporating prior Knowledge Graph into dual Wasserstein Generative Adversarial Network with gradient penalty," *Appl. Soft Comput.*, vol. 139, p. 110151, 2023, doi: 10.1016/j.asoc.2023.110151.
- 24) S. Aggarwal, S. Singh, S. Aggarwal, and S. Chandra, "Seminars in Cancer Biology Drug repurposing for breast cancer therapy : Old weapon for new battle," *Semin. Cancer Biol.*, vol. 68, no. September 2019, pp. 8–20, 2021, doi: 10.1016/j.semcancer.2019.09.012.
- 25) Y. Jung, Y. Kim, and Y. Cho, "Comparative analysis of network-based approaches and machine learning algorithms for predicting drug-target interactions," *Methods*, vol. 198, no. October 2021, pp. 19–31, 2023, doi: 10.1016/j.ymeth.2021.10.007.
- 26) J. Zhang, Z. Liu, Y. Pan, H. Lin, and Y. Zhang, "IMAEN : An interpretable molecular augmentation model for drug – target interaction prediction," vol. 238, no. September 2023, 2024.